Skip to content
DXCM·Nasdaq·US

Dexcom

Dexcom is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. It sells its products, including the Dexcom G7, G7 15 Day, Dexcom ONE+, and Stelo biosensor, to people with diabetes and those seeking to optimize metabolic health, and competes in the intensely competitive glucose monitoring device industry.

Source: SEC 10-K Feb 12, 2026

Thematic Position

DXCM

Relationship Groups

Licensing1
Competitors2

Relationship details are part of the Pro plan.

Ended Relationships

1 ended relationship · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

state aid/reimbursement regulationcompetitive bidding
CMS extends DMEPOS competitive bidding program to CGMs starting 2027
SEC 10-KFeb 12, 2026

The full regulatory passage is part of the Pro plan.

4 more · Regulatory and geopolitical insights are part of the Pro plan.